23.06 0.00 (0.00%)
Pre-Market: 8:38AM EDT
|Bid||22.98 x 1000|
|Ask||23.11 x 4000|
|Day's Range||22.93 - 23.52|
|52 Week Range||10.85 - 33.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.43|
Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business. Teva’s 2017 Social Impact Report spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research. Operating as an ethical, enduring enterprise is critical to continue bringing value to our business, our stakeholders and society,” said Kåre Schultz, President and CEO of Teva.
On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.
Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.
The Food and Drug Administration issued a voluntary recall late Friday of high-blood pressure and heart drugs containing the ingredient valsartan because of impurity issues. Affected companies include Teva Pharmaceuticals Industries Ltd. (teva) Solco Healthcare, and Major Pharmaceuticals, the FDA said. The agency said valsartan used in the affected products contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.
Teva Pharmaceutical Industries Ltd. (TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2018 results and overall business environment.
On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.
TRENTON, N.J. (AP) — In a story July 6 about Teva Pharmaceuticals moving its U.S. headquarters to New Jersey, The Associated Press erroneously reported the amount in tax credits the firm is receiving. The state's Economic Development authority approved about $40 million in credits over 10 years, not about $4 million in total credits over that period.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial.
As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.
Pennsylvania economic development officials weren't enticed to make a competing offer to keep Teva in the Philadelphia region, putting its presence in the suburbs in a precarious position.
During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.
Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...
On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.
Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.
Teva will relocate its North American headquarters to New Jersey, leaving questions about future of its operations in other states, including Kansas.
On July 3, the Financial Times reported that Pfizer Inc. (NYSE:PFE) is increasing the prices of 100 of its drugs by around 10 percent. Value investors looking to buy in should stick with drug stocks trading at favorable valuations and whose business faces multiple positive catalysts ahead. Here are 5 biotech stocks to get you started for July.
The generic drug manufacturer, which has about 2,000 employees in the Philadelphia suburbs, said it will continue to have a 'significant presence' in Pennsylvania.
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.